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The Myth Of Making Inferences For An
Overall Treatment Efficacy With Data From
Multiple Comparative Studies Via
Meta-analysis
Takahiro Hasegawa, Brian Claggett, Lu Tian, Scott D. Solomon, Marc A. Pfeffer,
and Lee-Jen Wei
Abstract
Meta analysis techniques, if applied appropriately, can provide a summary of the
totality of evidence regarding an overall difference between a new treatment and a
control group using data from multiple comparative clinical studies. The standard
meta analysis procedures, however, may not give a meaningful between-group
difference summary measure or identify a meaningful patient population of in-
terest, especially when the fixed effect model assumption is not met. Moreover,
a single between-group comparison measure without a reference value obtained
from patients in the control arm would likely not be informative enough for clin-
ical decision making. In this paper, we propose a simple, robust procedure based
on a mixture population concept and provide a clinically meaningful group con-
trast summary for a well-defined target population. We use the data from a recent
meta analysis for evaluating statin therapies with respect to the incidence of fatal
stroke events to illustrate the issues associated with the standard meta analysis
procedures as well as the advantages of our simple proposal.
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1. Introduction 
 
In comparing two treatments (for example, a new intervention vs. 
standard care) using the data from multiple studies, meta 
analysis can be a powerful tool to combine information across the 
studies for evaluating an overall group difference. As an example, 
recently Taylor et al. performed an extensive meta analysis to 
assess the effects, both risk and benefit, from various statins [1]. 
The meta analysis included randomized controlled clinical trials of 
statins vs. placebo or the standard care control with minimum 
duration of one year and follow-up of six months in people without 
a past history of cardiovascular disease (CVD). There are various 
outcome variables considered in their meta analysis. Here we 
consider the case with the fatal stroke event as the outcome of 
interest. In Table 1, we report the data from three studies: 
CARDS, JUPITER and WOSCOPS.  The observed risk ratios 
(RRs) of statin to control across the three studies range from 0.14 
to 1.43. A standard method for combining these RRs would be 
based on the Mantel–Haenszel procedure assuming a fixed-effect 
model [2, 3]. That is, we assume that the true RRs are the same 
across three studies. Under this assumption, the resulting 
estimated RR is 1.14 with a 95% confidence interval of (0.78, 1.66), 
indicating there is no significantly increased risk for fatal stroke 
associated with either treatment option. This estimate is 
essentially a weighted average of the observed study-specific RRs. 
The weights depend on the data. When the fixed-effect model 
assumption is plausible, one may interpret that for each study 
population in Table 1, the increase in risk associated with the 
statin could be about 14%. Note that since there is no summary 
measure for the event rate across the studies for either treatment 
group, it is not clear how to interpret whether or not a 14% risk 
increase would be clinically meaningful. This is a common 
http://biostats.bepress.com/harvardbiostat/paper207
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problem for the conventional meta analysis even when the fixed 
effect model assumption is plausible. 
 
 
Table 1. Risk of fatal stroke events for statin and standard care 
 
Study 
Control Statin Risk ratio 
(RR)* 
[95% CI] 
N Events N Events 
CARDS [4] 1412 7 1429 1 
0.14 
[0.02-1.15] 
JUPITER [5] 8901 6 8901 3 
0.50 
[0.13-2.00] 
WOSCOPS [6] 3293 37 3302 53 
1.43 
[0.94-2.17] 
* The risk ratio is defined as the event rate in the statin group divided by the event 
rate in the control group. 
 
Empirically, Taylor et al. [1] found that the above fixed-effect model is 
not appropriate for the data in Table 1, evidenced by a p-value of 0.04 
from a standard heterogeneity lack of fit test.  The weights used to 
derive the fixed-effect estimate of 1.14 depend on the underlying study-
specific event rates in a rather complex, data-dependent form. When the 
fixed-effect assumption is not reasonable, it is difficult, if not 
impossible, to interpret the meaning of the weights used or to what 
patient population the estimated RR would apply. 
 
 Instead of using the fixed effect model, Taylor et al. utilized a 
random-effects model [7] to combine the data across the studies. Under 
the random-effects framework, one assumes that the three observed 
studies were random samples from a hypothetical “super-population” of 
studies and that the true treatment contrast may differ from one study 
to another but follows a specific distribution across the super-population 
of studies. The resulting RR estimate, allowing for such heterogeneity 
between studies, is a 37% decrease in risk associated with statin use 
Hosted by The Berkeley Electronic Press
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and with a wide 95% confidence interval [RR=0.63, (0.18-2.23)]. It is 
interesting to note that numerically the RR estimates for the fixed and 
random effects appear to be quite different. This estimate is also a 
weighted average of observed study-specific risk ratios and the weights 
used depend on the underlying study-specific event rates.  Note that the 
random effect model procedure may be considered as a mixture 
population approach as discussed using Bayesian hierarchical modeling 
approaches [8, 9].  
 
There are several issues with this random effects model approach. 
Firstly, the resulting confidence interval when the number of studies is 
small (here, only three studies in the meta analysis) may not have the 
correct coverage level, a well-known fact in the statistical literature [10, 
11]. This limitation has recently been pointed out in an excellent, 
extensive review article by Cornell et al. [12] in the clinical literature 
along with three specific alternative methods which attempt to account 
for the increased uncertainty induced by between-study differences. 
However, these improved alternatives do not address a fundamental 
issue regarding random-effects meta analysis. That is, the previously 
mentioned hypothetical “super-population” of studies is generally not a 
well-defined or easily understood concept.  For example, it is difficult to 
determine if the inference results based on a random effects model 
would be applicable to a new study population since there is often no 
clear rule to determine if the new study of interest belongs to the 
“super-population” of studies. Because of this, the resulting estimated 
RR cannot be viewed as a valid estimate of the true RR for any of the 
three patient populations or a future target population. Even if there is 
a well-defined super-population, a complete summary of the between-
group difference cannot be conveyed without a description of the full 
distribution of the estimated random effects, not just its center (e.g., 
average) value [13]. However, this approach poses additional technical 
challenges and has been rarely employed in practice.  Furthermore, the 
validity of the resulting point and interval estimates requires a strong 
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distributional assumption (for example, normal distribution for the 
random effects) regarding the true RR's across all of the studies from 
the super-population, an assumption that may easily be misspecified 
and is difficult to justify empirically. Lastly, as in the fixed-effect 
modeling approach, there is no obvious summary event rate estimate 
for each strategy to interpret whether a potential 37% reduction in risk 
for the statins relative to the control would represent a clinically 
meaningful difference.  
 
As described, the standard procedures for meta analysis do not 
identify a target patient population of interest or utilize a clinically 
meaningful summary to quantify the between-group difference, 
especially when the fixed effect model assumption is not met. Therefore, 
there is a resurrected interest in conducting simple pooling analysis, 
where data from individual studies are pooled by the treatment group, 
and analyzed as if from a single study. However, the pooling analysis 
still does not identify a target population, Moreover, when the 
treatment allocation rates vary across individual studies, this analysis 
may yield spurious results [14, 15].   
 
In the next section, we use the above example to illustrate a simple, 
robust procedure via the well-known mixture model approach [16, 17] to 
combine information across multiple studies. This procedure can 
identify a target study population and a simple, meaningful group 
contrast summary measure with an overall estimated event rate from 
the control arm, which can be used as a reference value for clinical 
decision making. In this paper, we first consider the case that only 
summary data for the patients’ baseline covariates and outcomes are 
available from individual studies. To combine information for the 
between-group comparisons, the ideal situation is to have patient-level 
data from individual studies so that we may be able to make efficient 
inference for a target population with a pre-specified joint covariate 
distribution or its summaries thereof. We discuss a potential approach 
Hosted by The Berkeley Electronic Press
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to handle the case that we are interested in a pre-specified target 
population. We use the data from a large global cardiovascular clinical 
trial by treating each sub-study conducted in a country involved as the 
individual study in the meta analysis.     
 
2. Identifying a mixture, target population and estimating an overall 
group difference 
 
To illustrate our simple approach, consider the aforementioned 
comparison of fatal stroke rates between the standard care and statins. 
Note that like other meta analyses, there was no target population of 
interest pre-specified in this meta analysis. The selection process of 
studies was driven by the availability of data [4–6]. The first question is 
whether we can use available information in the literature to identify a 
potential target population from this specific meta analysis. For each of 
the three clinical studies, there is a parent patient population well 
specified in its study protocol (for example, via the study inclusion and 
exclusion criteria based on the subjects' baseline covariates). However, 
only summary data including the study patients’ baseline 
characteristics for individual studies are available in the publications. 
In Table 2, we provide an empirical summary of some of the patients' 
baseline characteristics (e.g., average age, proportion of males, average 
BMI, average LDL, average SBP and DBP) from each of the three 
studies available in the literature. These summaries empirically  
characterize the patients’ profiles of the underlying study populations. 
Note that these three study populations seem rather different, for 
example, with respect to the proportion of males in each study (ranging 
from 62% to 100%) as well as patients' average LDL cholesterol 
(ranging from 2.79 mmol/L to 4.97 mmol/L). Within the random effects 
modeling framework, it is not clear from which “super population” these 
studies were selected. 
 
http://biostats.bepress.com/harvardbiostat/paper207
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Table 2. A summary of baseline characteristics from each of the three 
studies 
 
Study 
Mean 
age 
(years) 
Male 
(%) 
Mean 
BMI* 
(kg/m2) 
Mean 
LDL* 
(mmol/L) 
Mean 
SBP* 
(mm Hg) 
Mean 
DBP* 
(mm Hg) 
CARDS [4] 62 68 29 3.03 144 83 
JUPITER [5] 66 62 28 2.79 134 80 
WOSCOPS [6] 55 100 26 4.97 135 84 
* BMI = body mass index. LDL = low-density lipoprotein. SBP = systolic blood 
pressure. DBP = diastolic blood pressure. 
 
A possible target population can be constructed via a mixture of 𝐾 
individual study populations in the meta analysis. To this end, assume 
that 𝑃𝑘  and 𝐹𝑘(𝒙) are, respectively, the 𝑘
th patient population and the 
corresponding cumulative joint distribution function of the patients' 
baseline covariate vector 𝒙 = (𝑥1, ⋯ , 𝑥𝑝)′ for 𝑘 = 1, ⋯ , 𝐾. Note that these 
populations may be overlapped. The 𝐹𝑘(𝒙) may be estimated with the 
patients’ level data from the 𝑘th  study, 𝑘 = 1, ⋯ , 𝐾.   If there are no 
patient level data, the summaries in Table 2 may be used to 
characterize a target population. A mixture population ℙ of these 𝐾 
populations with a set of nonnegative weights 𝒘 = (𝑤1, ⋯ , 𝑤𝐾)′, where 
∑ 𝑤𝑘
𝐾
𝑘=1 = 1 , represents a patient population consisting of these 𝐾 
populations. A typical subject of this mixing population is obtained as 
follows. First, we generate a multinomial random variable from 
{1, ⋯ , 𝐾} with cell probabilities {𝑤𝑘}. Suppose that the realization is  𝑘, 
then the subject is chosen randomly from 𝑃𝑘 . The cumulative 
distribution function of the covariates of this mixture, target population 
would be 𝐹0(𝒙) = ∑ 𝑤𝑘𝐹𝑘(𝒙)
𝐾
𝑘=1 . In the following, we assume that the 
parameter of interest is 𝜃 = 𝑔(𝑝1, 𝑝0) , a contrast between 𝑝1  and 𝑝0, 
where 𝑝𝑗  is the underlying event rate of group 𝑗  in the mixture 
population ℙ. If 𝑔(𝑥, 𝑦) = 𝑥/𝑦 , then 𝜃 is RR, as used in the example 
above. 
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To make inference about 𝜃, one needs to specify the target population 
𝑃0 by choosing the mixing proportions. The mixing weights {𝑤𝑘} can be 
chosen to be reflective of the relative “clinical importance and 
relevance” of the individual study populations. As an example using the 
above meta analysis, we might consider those three study populations 
to be equally important with a weight of 1/3 each. With this set of 
mixing weights, the average age, proportion of males, average BMI, 
average LDL, average SBP and DBP are approximately 61 years, 77% 
male, 28 kg/m2, 3.60 mmol/L, 138 mmHg, and 82 mmHg, respectively in 
this “equal-mixture” target population. If more detailed information is 
available from the publications of these three parent studies, one can 
further characterize this target population in terms of other relevant 
patients’ characteristics. For instance, the standard deviation for 
continuous variables could be obtained for this mixture population 
based on the standard deviations reported in the papers of the three 
studies if available.   
 
The inference for 𝜃 in this case is straightforward. For example, (𝜃 −
𝜃) can be approximated by a mean zero normal distribution with a 
variance of  
?̂?2 =  ?̇?1
2(?̂?1, ?̂?0) ∑
𝑤𝑘
2?̂?𝑘1(1 − ?̂?𝑘1)
𝑛𝑘1
𝐾
𝑘=1
+ ?̇?0
2(?̂?1, ?̂?0) ∑
𝑤𝑘
2?̂?𝑘0(1 − ?̂?𝑘0)
𝑛𝑘0
𝐾
𝑘=1
, 
where 𝜃 = 𝑔(?̂?1, ?̂?0), ?̂?𝑗 = ∑ 𝑤𝑘?̂?𝑘𝑗
𝐾
𝑘=1 ,  ?̂?𝑘𝑗  is the observed event rate in 
the group j of the 𝑘th study with 𝑛𝑘𝑗  observations and ?̇?𝑗(𝑝1, 𝑝0) is the 
partial derivative of 𝑔(𝑝1, 𝑝0) with respect to 𝑝𝑗. The confidence interval 
for 𝜃 can then be constructed accordingly.  
 
Now, with the data from the above fatal stroke meta analysis, for this 
“equal-mixture” population ℙ, we may first estimate the event rate for 
the control group using a simple average of its three observed event 
rates: 0.50%, 0.07%, and 1.12% from Table 1. This results in an 
estimate of 0.56%: 
http://biostats.bepress.com/harvardbiostat/paper207
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(0.50%×33.3%) + (0.07%×33.3%) + (1.12%×33.3%) = 0.56%. 
 
Similarly we obtain an average event rate for the statin arm, which is 
0.57%. Then the underlying RR between the two treatment groups is 
the ratio of the two event rates can be estimated as 0.57%/0.56% (=1.01) 
with a 95% confidence interval of (0.67, 1.53). Note that the 
interpretation of the estimated RR of 1.01, coupled with the two 
estimated event rates 0.57% and 0.56% for the statin and control is 
more informative for clinical decision making. Moreover, this simple 
mixture approach allows for the use of different metrics to quantify the 
between-group difference. For instance, one can easily obtain the 
absolute risk difference estimate and numbers needed to treat (NNT) or 
harm (NNH).  For this specific mixture population, the risk difference 
would be 0.01% with a 95% confidence interval of (-0.22%, 0.24%). 
 
Rather than assuming that each study population is equally clinically 
relevant, we may consider a scenario that the study sample size is 
reflective of how common certain types of patients are in the general 
population, suggesting that the study weights should be proportional to 
the study sample size. For the present example, the study weights 
would be 10.4%, 65.4%, and 24.2%, respectively. In this "study size 
mixture" target population, the average age, proportion of males, 
average BMI, average LDL, average SBP and DBP are approximately 
63 years, 72% male, 28 kg/m2, 3.34 mmol/L, 135 mmHg, and 81 mmHg, 
respectively. The event rates are estimated to be 0.42% for the statin 
group and 0.37% for the control group. Then the RR is 1.14 with a 95% 
confidence interval of (0.77, 1.67). Note that for this mixture population, 
the observed event rates are lower than those for the mixture 
population with the equal mixing weights discussed above. The 
summaries of the patients’ baseline characteristics indicate that this 
second population contains relatively more females and has lower 
average LDL and blood pressure values. We may be able to differentiate 
these two populations further if more information about the patients’ 
Hosted by The Berkeley Electronic Press
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baseline characteristics is available in the individual study-specific 
publications.  
 
3. Identifying a mixture population from studies in meta analysis to 
match a pre-specified target population 
 
A key principle in the conduct of a clinical study is to define the patient 
population first, then collect data in order to make inference about a 
certain characteristic of this population. Ideally, meta analyses should 
follow this principle as well. Once a well-defined target patient 
population has been established, for instance, with respect to the 
distribution 𝐹0(𝒙) of the patients' baseline variables, the investigator 
may select studies for the meta analysis whose parent populations are 
similar or relevant to the target patient population with respect to the 
distribution of the vector of baseline variables 𝒙. Now, let ?̂?𝑘(𝒙) be the 
empirical distribution function for the 𝑘th study, 𝑘 = 1, ⋯ , 𝐾. Then, in 
theory, one may choose the mixing weights ?̂? = (?̂?1, ⋯ , ?̂?𝐾)′ such that 
∑ ?̂?𝑘?̂?𝑘(𝒙)
𝐾
𝑘=1 ≈ 𝐹0(𝒙), for all 𝒙 in the support of the covariate vector. 
Note that the above equations may be relaxed by matching certain sets 
of moments of covariate variables, for example, via the mean values of 
covariates. In this section, we assume that we have the patient level 
data from individual studies.  
 
We use the data from a clinical trial, VALsartan In Acute myocardial 
iNfarcTion (VALIANT) trial, to illustrate our proposal [18].  This study 
is a multi-center double-blind randomized clinical trial comparing the 
effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor 
captopril and the combination of the two on mortality/mobility in 
patients with myocardial infraction, heart failure or both.  There are 
14703 patients with 30 baseline covariates from 24 countries.  We treat 
each sub-study conducted in a country as a “study” for the purposes of 
meta-analysis.  For illustration, the outcome of interest is the event of 
the first hospitalization or death during the first 18 months of the 
http://biostats.bepress.com/harvardbiostat/paper207
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follow-up and we compare the monotherapy treatments with the 
combination therapy by grouping the patients receiving either valsartan 
or captopril alone into a single arm. To simplify the illustration, five 
baseline covariates (age, history of diabetes, history of heart failure, 
history of stroke and usage of other diuretics) were selected as the most 
statistically important covariates via the standard logistic regression 
with the entire dataset.  There are 9737 and 4843 patients with 
complete covariate information in the monotherapy and combination 
therapy arms, respectively. The empirical means of those five baseline 
factors by country are summarized in Table 3. 
 
 
Table 3. A summary of baseline characteristics from each of the 24 
countries in VALIANT study. 
 
 
Country (n) 
Age, yrs 
(mean) 
Diabetes 
(%) 
Heart 
failure 
(%) 
Stroke 
(%) 
Usage of 
other 
diuretics (%) 
Argentina (633) 62.2 20.2 7.7 3.5 34.9 
Australia (306) 65.9 26.8 13.1 6.9 54.9 
Austria (26) 62.5 23.1 7.7 11.5 50.0 
Belgium (66) 67.4 22.7 4.5 6.1 24.2 
Brazil (213) 63.1 23.5 12.7 7.5 55.9 
Canada (1081) 66.8 29.4 15.8 6.7 60.3 
Czech (204) 65.7 25.5 6.4 4.9 36.3 
Germany (323) 63.4 21.4 9.3 5.3 52.3 
Denmark (674) 69.2 24.5 13.2 9.3 73.1 
Spain (122) 66.5 34.4 21.3 5.7 46.7 
France (161) 65.5 19.3 8.1 5.6 72.0 
United Kingdom (820) 64.4 21.2 5.1 4.1 47.1 
Hungary (396) 61.9 14.4 7.8 4.0 63.6 
Ireland (38) 68.5 21.1 7.9 7.9 47.4 
Italy (739) 66.4 20.0 7.0 3.4 59.5 
Netherlands (253) 67.9 24.5 5.5 4.7 65.2 
Norway (263) 70.6 27.8 17.1 5.7 91.3 
New Zealand (134) 67.9 29.1 8.2 6.7 67.9 
Poland (342) 63.0 28.1 14.0 6.1 43.9 
Russian Federation (3120) 63.6 36.2 24.1 7.0 43.8 
Slovakia (184) 62.8 23.4 9.2 4.9 33.3 
Hosted by The Berkeley Electronic Press
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Sweden (485) 72.1 29.3 12.4 7.4 73.2 
U.S.A. (3939) 63.7 29.4 16.0 6.4 43.4 
South Africa(58) 59.5 19.0 3.4 0.0 60.3 
Target 1* 65.3 28.2 15.1 6.1 53.2 
Target 2 61.0 25.0 10.0 5.0 45.0 
* The moments of this target population are set to be same as observed 
counterparts of all participants from Europe.  
 
 
 
 
In practice, the target population is generally described via certain 
summaries of individual covariates’ profiles (for example, the mean and 
standard deviation for a continuous covariate). Therefore, to obtain the 
weights {?̂?𝑘}, one may minimize the distance 
𝑀(𝒘) = ∑ [∑ 𝑤𝑘∫ 𝑚𝑙(𝒙)𝑑?̂?𝑘(𝒙)
𝐾
𝑘=1
− ∫ 𝑚𝑙(𝒙)𝑑𝐹0(𝒙)]
2𝐿
𝑙=1
  ,  
subject to the constraint 
∑ 𝑤𝑘
𝐾
𝑘=1
= 1  and  𝑤𝑘 ≥ 0, 𝑘 = 1, ⋯ , 𝐾, 
where 𝑚𝑙(𝒙)  is a function of the covariate vector for example, 
𝐸{𝑚𝑙(𝒙)} can be the first or second moment of a single covariate. That is, 
we approximate the distribution  𝐹0(𝒙) by a mixture of individual study-
specific empirical moments. When 𝐿 is small, one may not have enough 
information to uniquely define the mixture population, that is, there are 
multiple sets of weights matching the target population perfectly, i.e., 
∑ 𝑤𝑘∫ 𝑚𝑙(𝒙)𝑑?̂?𝑘(𝒙)
𝐾
𝑘=1 = ∫ 𝑚𝑙(𝒙)𝑑𝐹0(𝒙), 𝑙 = 1, ⋯ , 𝐿.     
 
In the VALIANT study, if we let the covariate means of the target 
population be the observed empirical averages of all participants from 
Europe (see Target 1 of Table 3), i.e., 𝑚𝑙(𝒙) = 𝑥𝑙 , 𝑙 = 1, ⋯ , 5, there are 
multiple ways to form the mixture population matched with the desired 
http://biostats.bepress.com/harvardbiostat/paper207
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covariate means. For example, it is straightforward to verify that both 
weights 
?̂?1 =(4.0, 1.7, 0.0, 0.0, 0.0, 7.8, 0.6, 1.6, 5.0, 1.8, 1.5, 5.2, 3.1, 0.3, 6.8, 
2.2, 5.2, 0.1, 1.0, 20.7, 0.1, 5.0, 26.0, 0.1)% 
and  
?̂?2 =(3.7, 5.5, 0.3, 0.3, 5.1, 7.4, 2.1, 3.5, 3.4, 12.4, 1.5, 1.0, 2.3, 0.9, 1.9, 
0.2, 7.0, 1.6, 7.3, 14.5, 4.4, 3.5, 8.6, 1.5)% 
can be used to match the specified covariate means.  In fact, there are 
infinite number of weights {𝑤𝑘} satisfying the constraints. While all the 
candidate weights generate a target population with desired moments, 
we may prefer to more efficiently utilize the observed data for making 
inferences about the treatment difference.  Intuitively, one would assign 
a relatively large weight for a large study. Specifically, we may choose 
the mixing weight solving the original optimization problem and also 
minimizing the loss function  
𝐷(𝒘) = ∑(𝑤𝑘 − 𝜋𝑘)
2
𝐾
𝑘=1
, 
where 𝒘 = (𝑤1, ⋯ , 𝑤𝐾) and 𝜋𝑘 is the proportion of the patients from the 
𝑘th study/country in the combined patient cohort.  In this case, the 
solution is ?̂?1 given above. 
 
 
Now, suppose that there is a unique solution 𝒘 to the limit of 𝐷(𝒘) 
subjects to all the constraints, and also a unique solution ?̂? =
(?̂?1, ⋯ , ?̂?𝐾)
′  to 𝐷(𝒘). Under certain regularity conditions, ?̂? converges 
to 𝒘 = (𝑤1, ⋯ , 𝑤𝐾)
′ in probability as the sample sizes of all studies go to 
infinity. Furthermore, if we assume that 0 < 𝑤𝑘 < 1, 𝑘 = 1, ⋯ , 𝐾, then 
(?̂? − 𝒘)  can be approximated well by a mean zero Gaussian 
distribution. With slight abuse of notation, 𝜃, the parameter of interest, 
is the underlying between group contrast in the mixture population 
with weights 𝒘. To make inferences about the between-group difference 
𝜃, consider the aforementioned heart failure incidence example. For this 
case, a consistent estimator for 𝜃 is  
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𝜃 = 𝑔(?̂?1, ?̂?0), 
where 
?̂?𝑗 = ∑ ?̂?𝑘?̂?𝑘𝑗
𝐾
𝑘=1
, 𝑗 = 0, 1.  
Furthermore, by the delta method, the distribution of (?̂? − 𝜃) can be 
approximated by a normal distribution 𝑁(0, 𝜎2).  The variance 𝜎2 can be 
estimated via a resampling method, for example, bootstrapping.  Note 
that the weights ?̂? are also random. One needs the patient level data 
from individual studies to obtain a consistent estimator for this limiting 
variance.  
 
 
In the VALIANT example, if we choose ?̂?1, the minimizer of 𝐷(𝒘), as 
the mixing weights, the estimated incidence rate of hospitalization or 
death during the first 18 months of the study is 57.43% and 57.65% for 
the combination therapy and mono therapy arms, respectively.  Thus, 
the treatment effect measure of the difference of incidence rates 
between the two arms is -0.22%.  To obtain a confidence interval, we 
bootstrapped individual patients within each of the study to account for 
the variations of both the weights and study-specific treatment effect 
estimator. The estimated standard error is 0.96% and the corresponding 
95% confidence interval is (-2.10%, 1.66%), suggesting that the 
treatment effect, if any, is relatively small in magnitude.  On the other 
hand, if we prefer less variation in weights across studies, we may use 
the modified loss function 
𝐷(𝒘) = ∑(𝑤𝑘 − 𝐾
−1)2
𝐾
𝑘=1
 
to guide the selection of the mixing weight.  The resulting mixing 
weight is ?̂?𝟐  and the estimated treatment effect is 1.67% (-4.81%, 
1.73%).  Note that the variance of this estimator triples that of the 
previous estimator with the weights selected via the study sizes, which 
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demonstrates the important role of the study sizes in improving the 
precision of the inference procedure.  
 
The requirement of individual patient data for making statistical 
inference when the weights are data dependent can be difficult to meet 
in practice.  However, the individual level data are needed to estimate 
the joint distribution of ?̂?  and the study-specific treatment effect 
estimates (𝜃1, ⋯ , 𝜃𝐾)′.  If we ignore correlations between the two, the 
variance of 𝜃 can be approximated with only study-level summary data. 
In the VALIANT study, the resulting variance estimator is very close to 
that based in individual patient data. However, such an observation 
may not be reproducible in other settings.  
 
For certain situations, we may not be able to create a mixture of 
individual study populations to perfectly match those pre-specified 
moments of the target population, especially when 𝐿 ≥ 𝐾. For example, 
in VALIANT study, if we consider the second target population in Table 
3, representing a younger (mean age 61) and healthier population (25% 
diabetic, 10% with heart failure, 5% with stroke, 45% diuretic use) than 
the European patients, then there is no set of weights which would 
produce a perfect match with 𝑀(𝒘) = 0.   If we search for the most 
similar mixture population by minimizing 𝑀(𝒘) , then the resulting 
population consists of patients only from Austria, Russia Federation, 
Slovakia and South Africa.  In general, we may check whether the 
empirical moments of the resulting mixture population specified above 
are similar to those for the target population. If they are not similar in a 
practical sense, the resulting mixture population would not be a good 
approximation to the target population. In the above example, the 
covariate means are 61.9 years for age, 24.5% for diabetic history, 
10.2% for history of heart failure, 4.9% for history of stroke and 46.8% 
for other diuretics usage, which are close to the specified levels of the 
target population.  The treatment effect estimator is -3.86% with a 
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much wider confidence interval of (-14.61%, 6.89%) based on bootstrap 
methods. 
 
 
 
It is interesting to note that all the matchable covariate mean vectors 
consist the convex hull generated by points in 𝑅𝐿  representing the 
observed covariate means in each of the studies.  For demonstration 
purposes, we consider to match only age and history of diabetes in the 
VALIANT study. In this setting, Figure 1 shows the convex hull within 
which all the combinations of age and history of diabetes can be 
matched using those from the 24 studies.  For example, (61 years, 25%) 
is within the convex hull and indeed if we weigh Poland, Russia 
Federation and South Africa by 3.1% 33.3% and 63.5%, respectively, 
then we can match the average age of 61 years and diabetic prevalence 
of 25%. The sparseness in weight is a reflection of the fact that (61 
years, 25%) is very close to the boundary of the convex hull.  It is also 
clear that (61 years, 30%) is outside the constraint set and thus there is 
no mixture population with an average age of 61 years and a diabetic 
prevalence of 30%. However, using our proposal, we may find the best 
approximation to the target population, whose mean is (62 years, 29%) 
marked on the Figure 1.  
 
 
Figure 1: Matchable combinations of age and history of diabetes in 
Valiant study and the graphic demonstration of approximating an 
unmatchable target populatin. 
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For the conventional meta analysis, we obtain each study-specific 
between-group risk ratio first, and then combine them across studies 
using weights that depend on, for example, study-specific event rates. 
The resulting overall estimate and reference population may be difficult 
to interpret clinically or may fail to represent a meaningful patient 
population. Instead we recommend obtaining an overall event rate 
estimate from an interpretable mixture of study populations for each 
treatment group first, and then construct the between-group difference 
measure. This approach does not require any modeling assumptions 
and provides a clinically interpretable empirical group difference 
estimate for a well-defined study population. Moreover, this procedure 
also provides the overall event rate estimates for two groups (for 
example, 0.37% vs 0.42% for fatal stroke incidence for the control and 
statin groups), allowing for the interpretation of the relative risk ratio 
in a more meaningful way. Note that like other meta analysis methods, 
the inference procedure for this simple proposal may not perform well 
when there are studies with zero events. An exact inference procedure 
may be needed to handle this situation. 
 
It is important to note that the above approach is quite different from 
the controversial “pooling analysis.” For pooling analyses, we would 
combine the “statin therapy” patients from all three studies to obtain 
the event rate estimate, and then similarly for the “control therapy” 
patients. Then the RR would be constructed from these two estimated 
rates. In our example, the resulting RR estimate would be 1.14 with a 
95% confidence interval of (0.78, 1.66), which is not drastically different 
from the estimates for the above mixture population with weights 
proportional to the study sizes due to the fact that among these three 
studies, there is no study with a marked imbalance in sample size 
between the two groups. While our proposal is similar to pooling 
analysis with respect to simplicity of implementation, our proposal is 
flexible with respect to prespecified mixing proportion and importantly, 
remains valid when the treatment allocation proportions are different 
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across individual studies, while the pooling procedure may produce 
unreasonable results, reflecting Simpson’s paradox [19]. As an 
illustrative example, we consider the well known example of the study 
in gender bias among graduate school admissions at UC Berkeley (see 
Appendix for data). In the pooling analysis, the overall admission rate 
of males was 45% compared to 30% for females, suggesting an 
admissions processed that strongly favored male applicants. However, 
when applying our method using total number of applications per 
department as the weights, the resulting estimates are 39% acceptance 
for males and 43% for females, estimates much closer in magnitude and 
reversing the original suspected gender discrepancy. 
 
In time-to-event analyses, the conventional meta analysis procedure 
is to estimate each study-specific hazard ratio and obtain a weighted 
average of those hazard ratio estimates. The interpretability of the 
resulting estimate depends on two strong model assumptions: i) the 
proportional hazards assumption within each study; and ii) the equality 
of all underlying study-specific hazard ratios. With the mixture 
population model approach, we cannot obtain a weighted average of the 
study-specific hazard functions for each group due to the fact that the 
hazard function is not a probability. On the other hand, an alternative 
summary measure such as the event rate or the restricted mean 
survival time at a specific follow-up time point can be considered for 
each group [20, 21]. We may then similarly obtain an estimate based on 
an interpretable mixture of these study-specific event rates (or 
restricted mean event times) across all studies to construct a group 
contrast measure for a target mixture population. 
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Appendix: Data Set for Graduate Admissions Example 
 Male Female 
Department applicants accepted applicants accepted 
A 825 512 108 89 
B 560 353 25 17 
C 325 120 593 202 
D 417 138 375 131 
E 191 53 393 94 
F 373 22 341 24 
total 2691 1198 1835 557 
 
http://biostats.bepress.com/harvardbiostat/paper207
